Marketing Shyness and Neurotransmitters

Christopher Lane, author of Shyness: How Normal Behavior Became a Sickness, was recently interviewed by the Chicago Tribune. I got this courtesy of Ken Pope. Here’s how the interview ended:

Q: The diagnosis “social anxiety disorder” opened up a huge new market
for drug companies marketing SSRIs (selective serotonin reuptake
inhibitors). What happened?

A: Basically, as soon as SmithKline Beecham (now GlaxoSmithKline) got
FDA approval to sell Paxil as a treatment for social anxiety
disorder … they ran a very expensive public awareness campaign. It was
the “Imagine being allergic to people” campaign. It cost them $93
million – $3 million more than Pfizer spent that year on Viagra.

As they bragged in Advertising Age, it was a way of increasing the
number of diagnoses and creating a new market. First they had to
convince people they weren’t just shy – that they had social anxiety disorder.

Q: Why would people accept that diagnosis?

A: It’s a fascinating question, and a complicated one. You have the
apparent reassurance of a scientific label. You can say, my problem
isn’t to do with me or my psychology or my upbringing.

The label is a strange distancing device. Because it means one needn’t
really think about oneself in the process. It’s really a question of my
neurotransmitters.

Please click on the green button if you found that post interesting. Thanks.
Add to Technorati Favorites
Kalea Chapman, Psy.D.

Advertisements

Published by

kaleachapmanpsyd

Clinical Psychologist practicing in the Los Feliz neighborhood of Los Angeles, California.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s